Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…
A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.
Summary: In 178 adults with T2D (HbA1c 7.0-10.5%) on stable metformin, once-weekly semaglutide (0.25-1.0 mg) for 52 weeks produced numerically…
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.